Table 2.
Trial | Therapy Group | No. of Participants |
Baseline Mean TBV, cm3a |
TBV, Mean (95% CI), cm3b | P Valuec | |
---|---|---|---|---|---|---|
40 mo | Change From Baseline | |||||
Blood pressure | INT | 153 | 921.5 | 902.6 (900.2 to 905.0) | −18.9 (−21.3 to −16.5) | |
STD | 161 | 921.5 | 907.0 (904.7 to 909.4) | −14.5 (−16.8 to −12.2) | ||
40-mo difference | −4.4 (−7.8 to −1.1) | .01 | ||||
Lipid | Fenofibrate | 89 | 937.0 | 924.1 (920.9 to 927.2) | −12.9 (−16.1 to −9.8) | |
Placebo | 100 | 937.0 | 922.9 (919.9 to 925.9) | −14.1 (−17.1 to −11.1) | ||
40-mo difference | 1.2 (−3.1 to 5.5) | .59 |
Abbreviations: INT, intensive; STD, standard; TBV, total brain volume.
Baseline mean is the overall mean for both groups combined as measured before randomization. This value is used to obtain the adjusted mean estimates at follow-up.
Indicates adjusted mean obtained from analysis of covariance.
Calculated as a test of difference between the intervention group means at the 40-month visit, adjusted for the baseline level of the outcome. When controlling for the baseline value of the outcome, the P value for a comparison of the 40-month means between intervention groups will be identical to the P value for a comparison of change from baseline (controlling for the baseline level as a covariate) to the 40-month visit.